Drug Profile

PTG 100

Alternative Names: PTG-100

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protagonist Therapeutics
Class Anti-inflammatories; Antiulcers; Disulfides; Peptides
Mechanism of Action Alpha4beta7 integrin antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Coeliac disease
Discontinued Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

28 Mar 2024 No recent reports of development identified for phase-I development in Coeliac disease in USA (PO, Capsule)
03 Apr 2022 Protagonist Therapeutics and Stanford University complete a phase I trial in Coeliac disease in USA (PO, Capsule) (NCT04524221)
26 Feb 2021 Phase-I clinical trials in Coeliac disease in USA (PO) (PTG-100-05-CeD)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com